Annexin A11 is associated with pulmonary fibrosis in African American patients with sarcoidosis

Not available.

[Glomerular filtration rate is an indicator of endothelial function at early stages of chronic kidney disease]

AIM

To study effects of glomerular filtration rate (GFR) reduction on endothelial function in patients at early stages of chronic renal kidney (CKD).

MATERIAL AND METHODS

Endothelial function of 101 patients with CKD of stage I-III was examined using reactive hyperemia test, dopplerography of skin vessels with ionophoresis of acetylcholin and nitroglycerin, lipidogram parameters, homocistein and annexin A5 levels, intima-media complex thickness of the common carotid artery, echocardiography findings.

RESULTS

Cardiovascular complications risk factors were found in all the patients: increased body mass index, arterial hypertension, dyslipoproteinemia, hyperhomocysteinemia. Reduced GFR (under 90 ml/min) is an independent factor of atherosclerosis risk.

CONCLUSION

GFR reduction corresponding to CRD of stage II is accompanied with enhancement of apoptosis and development of vasomotor endothelial dysfunction that in combination with risk factors contribute to development of a preclinical atherosclerosis phase.

Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome

Hemolytic uremic syndrome (HUS) is characterized by hemolytic anemia with fragmented erythrocytes, thrombocytopenia, and acute renal failure. Lack of complement inactivating factor H predisposes to the development of atypical HUS. Little is known about mechanisms linking complement activation with loss of erythrocyte integrity during HUS. Recent studies disclosed that increased cytosolic Ca2+ activity and cellular ceramide trigger programmed erythrocyte death or eryptosis, characterized by cell shrinkage and phosphatidylserine exposure at the erythrocyte surface. In the present study, we investigated whether eryptosis occurs during the course of HUS. To this end, erythrocytes from healthy volunteers were exposed to plasma from a patient with severe idiopathic recurrent HUS secondary to factor H depletion. Phosphatidylserine exposure (Annexin binding), cell volume (forward scatter), cytosolic Ca2+ activity (Fluo3 fluorescence), and ceramide formation [anti-ceramide antibody and enzymatic (diacylgycerol kinase) analysis] were determined. Exposure of erythrocytes to plasma from the patient, but not to plasma from healthy individuals, triggered Annexin binding. The effect of plasma on erythrocyte Annexin binding was abolished by plasmapheresis or filtration at 30 kDa. It was paralleled by formation of ceramide and increase of cytosolic Ca2+ activity. Enhanced Annexin binding of erythrocytes from healthy individuals was observed after exposure to plasma from three other patients with HUS. The proeryptotic effect of patient plasma was mimicked by exposure to the Ca2+ ionophore ionomycin, and eryptosis was potentiated in the presence of cell membrane-permeable C6-ceramide. Furthermore, in vitro complement activation similarly triggered erythrocyte phosphatidylserine exposure, an effect which was blunted by the addition of factor H. In conclusion, our present observations disclose a novel, pathophysiological, factor-H dependent mechanism leading to injury of erythrocytes during the course of hemolytic uremic syndrome.

In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia

BACKGROUND AND OBJECTIVES

Oxidant damage is an important contributor to the premature destruction of erythrocytes and anemia in thalassemias. To assess the extent of oxidant damage of circulating erythrocytes and the effects of antioxidant therapy on erythrocyte characteristics and anemia, we used a mouse model of human beta-thalassemia intermedia (b1/b2 deletion).

DESIGN AND METHODS

Several parameters indicative of oxidant damage were measured at baseline and following administration of the semi-synthetic flavonoid antioxidant, 7-monohydroxyethylrutoside (monoHER), to beta-thalassemic mice at a dose of either 500 mg/kg i.p. once a day (n=6) or 250 mg/kg i.p. twice a day (n=6) for 21 days.

RESULTS

Significant erythrocyte oxidant damage at baseline was indicated by: (i) dehydration, reduced cell K content, and up-regulated K-Cl co-transport; (ii) marked membrane externalization of phosphatidylserine; (iii) reduced plasma and membrane content of vitamin E; and (iv) increased membrane bound IgG. MonoHER treatment increased erythrocyte K content, and markedly improved all cellular indicators of oxidant stress and of lipid membrane peroxidation. While anemia did not improve, monoHER therapy reduced reticulocyte counts, improved survival of a fraction of red cells, and reduced ineffective erythropoiesis with decreased total bilirubin, lactate dehydrogenase and plasma iron.

INTERPRETATION AND CONCLUSIONS

Antioxidant therapy reverses several indicators of oxidant damage in vivo. These promising antioxidant effects of monoHER should be investigated further.

The presence of antiphospholipid antibodies is not related to increased levels of annexin A5 in plasma

Annexin A5 has been proposed to be important for shielding of negatively charged phospholipids from blood, thereby preventing the binding of clotting factors. It has been suggested that antiphospholipid antibodies can disrupt the binding of annexin A5 from negatively phospholipid-containing surfaces, resulting in uncontrolled coagulation. If this hypothesis is correct, than the plasma levels of annexin A5 will be increased in patients with antiphospholipid antibodies. Therefore, we have measured plasma levels of annexin A5 of 175 patients with systemic lupus erythematosus (SLE), of which 104 had antiphospholipid antibodies and 23 patients had primary antiphospholipid syndrome. The annexin A5 levels were compared with the annexin A5 plasma levels measured in 23 patients with diabetes mellitus type 2 and 35 healthy volunteers. We found a significant increase of annexin A5 plasma levels in patients with SLE (median 6.7 ng mL(-1)) and primary antiphospholipid syndrome (median 7.1 ng mL(-1)) as compared to patients with diabetes mellitus type 2 (median 3.3 ng mL(-1)) and healthy volunteers (median 3.9 ng mL(-1)). However, no correlation was found with the presence of antiphospholipid antibodies or with a history of thromboembolic complications. Based on these observations, we conclude that displacement of annexin A5 from cellular surfaces by antiphospholipid antibodies is not a common mechanism in patients with antiphospholipid antibodies.

Altered membrane phospholipid organization and erythrophagocytosis in E beta-thalassemia

The underlying cause behind the accelerated destruction of erythrocytes in the bone marrow and in the peripheral circulation, accompanying the beta-thalassemic syndromes is still not clearly understood. The present investigation demonstrates that increased phagocytosis of erythrocytes in E beta-thalassemia is inhibited by the presence of phosphatidylserine (PS) vesicles, suggesting a PS-'PS-receptor' type of interaction in premature recognition of these erythrocytes by macrophages. Increased exposure of both aminophospholipids phosphatidylethanolamine (PE) and PS was demonstrated by fluorescamine labeling and annexin binding, respectively. The slower rate of translocation of PS across the bilayer suggested that this contributed towards the increased exposure of PS in E beta-thalassemic erythrocytes.

Prolonged expression of procoagulant activity of human platelets degranulated by thrombin

Platelets are exposed to thrombin when they take part in arterial thrombus formation, and they may return to the circulation when they are freed by fibrinolysis and dislodged by flowing blood. Thrombin causes the expression of procoagulant activity on platelets, and if this activity persists, the recirculating platelets may contribute to subsequent thrombosis. We have developed techniques to degranulate human platelets by treatment with thrombin, and recover then as single, discrete platelets that aggregate in response to both weak and strong agonists. In the present study we examined the duration of procoagulant activity on the surface of thrombin-degranulated platelets by two methods: a prothrombinase assay, and the binding of 125I-labeled annexin. Control platelets generated 0.9 +/- 0.4 U thrombin per 10(7) platelets in 15 min. Suspensions of thrombin-degranulated platelets formed 5.4 +/- 0.1 U thrombin per 10(7) platelets in this time. Binding of 125I-annexin V was also greater with thrombin-treated platelets than with control platelets (controls: 1.7 +/- 0.1 ng annexin/10(7) platelets; thrombin-degranulated platelets: 6.8 +/- 0.2 ng annexin/10(7) platelets). With thrombin-degranulated platelets, increased procoagulant activity and annexin binding persisted for at least 4 h after degranulation and resuspension, indicating that the catalytic activity for the prothrombinase complex is not reversed during this time. These platelets maintained their ability to aggregate for 4 h, even in response to the weak agonist, ADP. Thus, platelets that have taken part in thrombus formation and returned to the circulation may contribute to the promotion of further thrombotic events because of the persistence of procoagulant activity on their surface.

Virtual lack of annexins in human platelets argues against a role in phospholipase A2 regulation and platelet secretion

Annexins are calcium-phospholipid binding proteins which share structural similarities and common biochemical properties. These proteins seem to be involved in different pathways of cell activation such as regulation of phospholipase A2 activity, membrane-cytoskeleton interaction, and exocytosis. The aim of this study was to attempt to characterize annexins in human platelets. Our results were based on specific EGTA extraction of proteins from platelet homogenates, immunodetection with specific antibodies raised against annexins I, II, V and VI, and measurement of phospholipase A2 inhibition. Antibodies raised against annexins I, V and VI revealed only trace amounts of these proteins in platelet EGTA extracts which did not promote phospholipase A2 inhibition in an in vitro assay. In addition, upon precipitation of membranes in the presence of calcium followed by EGTA extraction, the main substrate of protein kinase C (40-47-kDa protein) displayed a behaviour strictly different from that of annexins. Although one cannot exclude that a small amount of annexin(s) becomes phosphorylated in activated human platelets, these data argue against a role of annexins in the regulation of intracellular phospholipase A2 or in the processes of exocytosis in activated human platelets.

Evidence for the presence and location of annexins in human platelets

In this study the identity of annexins in human platelets has been determined together with their ability to be released by agents which induce platelet degranulation. The presence of proteins cross-reacting to antibodies against annexins I and V was detected in human platelets. However, the study provided evidence that these annexins are not located on the surface of the plasma membrane in a Ca++ dependent manner. Moreover, activation of platelets with several agents which induced platelet degranulation did not cause release of annexins I or V as determined by both immunoblotting and ELISA.

Calelectrin in human blood cells

Calelectrin is a new calcium-binding protein isolated from the cholinergic nerve terminals of the electric organ of Torpedo marmorata, which is widely distributed in nervous tissues and selectively binds to membranes, self-aggregates, and promotes calcium-induced membrane aggregation as a function of calcium concentration. We now show by immunofluorescence and immune blotting procedures that this protein is also present in human blood cells. Immunofluorescence demonstrates calelectrin in all human leucocytes, including mononuclear cells, but not in platelets or in erythrocytes. The immunofluorescence indicates an exclusively cytoplasmic location of calelectrin with a diffuse distribution and no primary association with the cytoskeleton or the cell membranes. SDS-polyacrylamide gel electrophoresis with immune blotting of fractionated blood cells (thrombocytes, mononuclear cells, granulocytes and erythrocytes) reveals the presence of a single protein crossreactive with calelectrin from Torpedo marmorata in the granulocyte and mononuclear cell fractions only. Human calelectrin has a molecular weight similar to Torpedo calelectrin (approximately 34-35 kD) and also binds to membranes in a Ca(2+)-dependent manner. Our results have several implications: (1) Calelectrin is conserved during evolution between the fish Torpedo marmorata and humans; (2) its expression in neural and mesenchymal cells points to an important functional role of the protein; (3) its absence from platelets excludes the hypothesis that it is a necessary participant in exocytosis per se and suggests some other function in Ca(2+)-triggered processes.